Mounting Evidence Questions Safety of BPA & Whether Science Guides Decisions at FDA

Statement

Mounting Evidence Questions Safety of BPA & Whether Science Guides Decisions at FDA

Congresswoman Rosa L. DeLauro (CT-3), chairwoman of the Agriculture - Food and Drug Administration Appropriations Subcommittee, issued a statement following the first large-scale study of Bisphenol A (BPA) in humans, which found that exposure to the chemical was associated with cardiovascular disease, type 2 diabetes and liver-enzyme abnormalities in adults. Appearing in the Journal of the American Medical Association, the study comes as the FDA scientific advisory committee holds a hearing on the use of BPA in products that make contact with food.

"The weight of scientific evidence on BPA points to the overwhelming to need protect American consumers, yet FDA continues to ignore the facts.

"The study of BPA in the Journal of the American Medical Association makes the third study in a month questioning the effects of BPA on people. While this study links the chemical to cardiovascular disease, type 2 diabetes and liver-enzyme abnormalities in adults, an earlier study by the National Toxicology Program at the National Institute of Health suggested that BPA can cause developmental problems in the brain and hormonal systems of infants and children. And another study by the Yale School of Medicine found a link between BPA and problems with brain function and mood disorders in monkeys.

"In fact, some companies are already acting to stop production of BPA products and removing products with BPA from their shelves.

"For the FDA to determine that BPA is safe for use in baby bottles is perplexing and dangerous. It is time for the FDA to allow science to guide its decision-making process."

Source